Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications

Area of Science:

• Urology
• Pharmacology

Background:

• Lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) require long-term management due to a 15-20 year life expectancy.
• Effective management necessitates sustained symptom control, improved quality of life (QOL), disease progression control (bladder wall hypertrophy [BWH]), and reduced need for alternative treatments.

Purpose of the Study:

• To evaluate alpha(1)-adrenoceptor antagonists as a first-line therapy for LUTS/BPH, considering both short-term and long-term outcomes.
• To assess the efficacy of tamsulosin in managing LUTS/BPH symptoms, QOL, and disease progression.

Main Methods:

• Review of pooled analyses and indirect comparisons of clinical studies up to 1 year.
• Examination of preliminary data on the effects of alpha(1)-adrenoceptor antagonists on bladder wall hypertrophy (BWH).

Main Results:

• Alpha(1)-adrenoceptor antagonists, such as tamsulosin, provide rapid and sustained symptom relief and QOL improvement for up to 6 years.
• Preliminary data suggest alpha(1)-adrenoceptor antagonists may prevent or reduce BWH.
• Tamsulosin reduces the risk of acute urinary retention and need for surgery, comparable to finasteride.
• Monotherapy with alpha(1)-adrenoceptor antagonists reduces long-term clinical progression risk.

Conclusions:

• Alpha(1)-adrenoceptor antagonists are effective first-line therapy for LUTS/BPH, offering sustained short-term and long-term benefits.
• Combination therapy with finasteride may benefit high-risk patients.
• Tamsulosin demonstrates efficacy in symptom control, QOL improvement, and potentially preventing BWH progression.